Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Comorbidity in HPV+ and HPV- oropharyngeal cancer patients: A population-based, case-control study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Upfront PET/CT affects management decisions in patients with recurrent head and neck squamous cell carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. MicroRNA-based classifiers for diagnosis of oral cavity squamous cell carcinoma in tissue and plasma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Development of depression in patients with oral cavity cancer: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Chronic rhinosinusitis in COPD: A prevalent but unrecognized comorbidity impacting health related quality of life

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Face masks for the prevention of COVID-19 - Rationale and design of the randomised controlled trial DANMASK-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Association between head and neck cancer and sexually transmitted diseases: a Danish nationwide, case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Circulating tumour DNA alterations as biomarkers for head and neck cancer: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

OBJECTIVES: Comorbid conditions impact outcome for patients treated for oropharyngeal squamous cell carcinoma (OPSCC) and serve as competing risk factors for death. The purpose of this study was to examine differences in comorbidities in patients with OPSCC and known HPV-DNA.

MATERIAL AND METHODS: We included patients diagnosed with OPSCC in Eastern Denmark in 2000-2014. Patients were linked to the Danish National Patient Register to identify comorbidities based on the Charlson Comorbidity Index (CCI) at time of diagnosis and following cancer treatment. Patients were age-and sex-matched in a 1:10 ratio with a reference group and stratified according to HPV-status.

RESULTS: In total 1,499 patients (55.0% HPV+) and 14,990 controls were included. Significantly more HPV+ patients had no comorbidities compared to HPV- patients at time of diagnosis (RR: 1.5 (1.3;1.6), n = HPV+: 522, HPV-: 302) and following treatment (RR 1.5 (1.4;1.6), n = HPV+: 342, HPV-: 142). Most prevalent comorbidity was malignancy not including OPSCCs. HPV+ patients had an increased risk of having AIDS before their OPSCC diagnosis compared to the reference population (OR: 4.8 (1.8;12.9)). HPV- patients had increased risk of multiple comorbidities including cerebrovascular disease (OR: 1.9 (1.4;2.5)), peripheral vascular disease (OR: 1.7 (1.9;3.7)), dementia (OR: 2.9 (1.4;5.8)), ulcer disease (OR: 2.6 (1.9;3.5)), liver disease, mild (OR: 9.5 (7.0;13.0)) and severe (OR: 13.9 (5.8;22.8)).

CONCLUSION: This study showed that HPV- patients had more comorbidities than HPV+ patients at the diagnosis time and following treatment. Irrespective of HPV-status, OPSCC patients had a significant increased risk of (secondary) malignancy compared to the reference population.

OriginalsprogEngelsk
TidsskriftOral Oncology
Vol/bind96
Sider (fra-til)1-6
Antal sider6
ISSN1368-8375
DOI
StatusUdgivet - 1 sep. 2019

Bibliografisk note

Copyright © 2019 Elsevier Ltd. All rights reserved.

ID: 58346344